Replimune secures FDA approval for RP1 therapy in advanced melanoma as Eli Lilly reports strong Q2 earnings

Replimune announced that the FDA has granted market approval for its oncolytic immunotherapy RP1, aimed at treating advanced melanoma. The decision follows two earlier rejections and a contentious advisory committee meeting.

Analysts estimate that the newly approved product, to be marketed under the name Tudriqev, could generate peak sales of around $1.3 billion if it gains traction in the oncology market.

In its second‑quarter earnings release, Eli Lilly reported revenue of $23 billion, a 48% increase from the same period last year. The company highlighted its oral GLP‑1 drug Foundayo, which posted $98 million in first‑quarter sales, though it trails Novo Nordisk’s oral Wegovy, which earned $355 million in its debut quarter.

The broader pharmaceutical landscape continues to see interest in emerging areas such as psychedelics, which remain a topic of discussion among investors and researchers.